BEAM THERAPEUTICS INC

Beam Therapeutics insider sale: CMO Simon Amy sells 373 shares amid a 81% YTD surge, showing disciplined ownership and long‑term confidence in DNA‑editing.

Beam Therapeutics’ insider trades show disciplined confidence: CEO sells options, buys shares, while FMR LLC buys 30%+ stake—positive signal for investors.

FMR LLC’s recent sale of Beam Therapeutics shares signals a strategic portfolio shift, underscoring the biotech’s high‑growth potential and insider activity that investors should watch closely.

Beam Therapeutics insider buys reveal confidence, not dilution: June 3 option exercises show board stability and long‑term optimism in gene‑editing.

Beam Therapeutics insider buys signal confidence in its base‑editing pipeline—key execs buy RSUs as the stock climbs, hinting at future upside.

Beam Therapeutics CEO buys 25k shares amid mixed sentiment – a clear sign of insider confidence and a potential buying opportunity for investors.

Beam Therapeutics’ President Giuseppe Ciaramella’s recent trades—buying at $17, selling at $32, and liquidating options—signal confidence, disciplined risk‑management, and a bullish outlook for the gene‑therapy company’s future.

Beam Therapeutics CEO’s Rule 10b5‑1 trades reveal a disciplined, long‑term confidence strategy, boosting ownership while generating modest liquidity.

Beam Therapeutics insider buying signals: SVP Finance Bethany Cavanagh’s 40k stock‑option purchase amid 52‑week lows hints at long‑term confidence in DNA base‑editing breakthroughs.

Beam Therapeutics insider selling: SVP of Finance sells 6,198 shares at $35 on Jan 22, 2026 – a routine 10b5‑1 plan move amid rising investor buzz and positive monthly gains.